Lanicor Ampullen (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on cardiac cells, leading to an increase in intracellular sodium. This change reduces the activity of the Na⁺/Ca²⁺ exchanger, causing calcium to accumulate inside the cell. The higher calcium concentration strengthens myocardial contraction and enhances vagal tone, which together lower heart rate and improve cardiac output.

The specific dose of digoxin administered via Lanicor Ampullen is individualized by the prescribing clinician based on factors such as the patient’s renal function, age, weight, and severity of disease. Physicians determine the appropriate loading and maintenance doses and adjust them according to therapeutic drug‑monitoring results.

Digoxin is classified as Pregnancy Category C, meaning risk to the fetus cannot be ruled out. It should only be used when the potential benefit justifies the potential risk. Limited data are available for breastfeeding, and the decision should be made by a healthcare professional weighing maternal benefit against possible infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lanicor Ampullen. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Compared with beta‑blockers or calcium‑channel blockers, digoxin provides rate control primarily through enhanced vagal tone rather than direct beta‑adrenergic blockade. It is especially useful in patients with reduced left‑ventricular function where negative inotropic effects of some alternatives are undesirable. However, digoxin requires careful monitoring for toxicity, whereas many other agents have broader therapeutic windows.

Lanicor Ampullen should be stored at ambient temperature, protected from light and moisture, and kept in its original packaging. The ampoules must not be frozen or shaken vigorously. Follow any specific handling instructions provided with the shipment to maintain product integrity.

The product is supplied as a sterile injectable ampoule for intravenous use. It is typically reconstituted with a compatible diluent according to the label instructions and administered slowly by a qualified healthcare professional, often as an initial loading dose followed by maintenance infusions, as directed by the prescriber.

The most critical risks involve digitalis toxicity, which can manifest as severe cardiac arrhythmias, profound bradycardia, heart block, or ventricular fibrillation. Elevated serum potassium (hyperkalemia) and electrolyte imbalances can exacerbate toxicity. Prompt recognition and measurement of serum digoxin levels are essential to prevent life‑threatening events.

Digoxin is contraindicated in patients with ventricular fibrillation, known hypersensitivity to digoxin or other cardiac glycosides, and in those with severe digitalis toxicity. Caution is also advised for individuals with significant renal impairment, uncontrolled electrolyte disturbances, or pre‑existing high‑grade AV block without a pacemaker.